Arrowstreet Capital
KRTX

Arrowstreet Capital’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Arrowstreet Capital’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,934
Closed -$2.23M – 1511
2022
Q3 		$2.23M Buy
9,934
+7,823
+371% +$1.58M ﹤0.01% 832
2022
Q2 		$267K Buy
+2,111
New +$243K ﹤0.01% 1136
2021
Q1 		– Sell
-11,400
Closed -$1.16M – 2611
2020
Q4 		$1.16M Buy
+11,400
New +$1.06M ﹤0.01% 1780

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital's KRTX Position: Q4 2022 in Review

Arrowstreet Capital sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 9,934 shares — an estimated $2.23M sold.

Arrowstreet Capital first reported a position in KRTX in Q4 2020 and held it in 3 quarters. The position peaked at $2.23M in Q3 2022. 248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

  • Arrowstreet Capital reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Arrowstreet Capital sold 9,934 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $2.23M.
  • Arrowstreet Capital first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Arrowstreet Capital's Karuna Therapeutics, Inc. Common Stock position peaked at $2.23M in Q3 2022.
  • 248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Arrowstreet Capital's 13F filing for Q4 2022, filed 14 Feb 2023.